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Langerhans Cells and Lymph Node Dendritic Cells
Express the Tight Junction Component Claudin-1
Simone C. Zimmerli1 and Conrad Hauser1,2
Claudin-1 is a critical structural component of tight junctions that have an important role in adhesive properties,
barrier function, and paracellular transport of epithelia and other nonhematopoietic tissues. We found claudin-
1 in murine CD207þ Langerhans cells (LC) residing in epidermis. Claudin-1 was not detected in other skin
dendritic cells (DC). LC expressed claudin-1 in steady state and inflamed skin. Claudin-1 was demonstrated
further in lymph node LC under steady state and inflammatory conditions, including after direct tracking with
tetramethylrhodamine-isothiocyanate (TRITC). All subsets of skin draining lymph node DC defined by CD205,
CD11b, CD11c, and CD8, including a presumably blood-borne lymph node resident CD8þCD207þ LC
population, were claudin-1þ . TRITC tracking demonstrated claudin-1 in CD207 skin migrant DC in the lymph
node, suggesting upregulation of this molecule during migration or once arrived in the lymph node. Claudin-1
expression in CD207þ cells was confirmed at the protein and mRNA levels. Transforming growth factor-b, a
factor critical for the induction of LC in vitro and in vivo, stimulated the accumulation of claudin-1 mRNA and
protein when added to bone marrow cells cultured with GM-CSF and IL-4. Claudin-1 may thus have an
important function in adhesion and/or migration of LC.
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INTRODUCTION
Langerhans cells (LC) are regarded as a subpopulation of
dendritic cells (DC) that are critical for the activation of naı¨ve
and resting memory T cells in vivo (Romani et al., 2003;
Valladeau and Saeland, 2005). LC differ from other DC subsets
by a number of surface markers notably CD207. CD207 is a
lectin-type receptor expressed on the surface of LC that can
internalize ligands into characteristic intracellular tubulovesi-
cular compartments termed ‘‘Birbeck granules,’’ the ultra-
structural hallmark of LC (Valladeau et al., 1999, 2000, 2002;
Hunger et al., 2004). CD207þ cells are found in stratified
epithelia such as epidermis, in secondary lymphoid organs
including lymph nodes and spleen, and in the lung. LC may
also differ from other DC subpopulations in function.
To understand divergent functions in LC and other DC
subsets, we performed a microarray analysis with LC-like
cells and myeloid DC-like cells induced in vitro from human
monocytes with a method described by Arrighi et al. (2003).
Claudin-1 scored higher in LC than DC, a result confirmed by
quantitative reverse transcriptase-PCR (RT-PCR) (unpublished
results).
Claudin-1 is a structural component of tight junctions
(Tsukita et al., 2000; Anderson et al., 2004; Turksen and Troy,
2004). It is a 23-kDa membrane protein with four transmem-
brane spanning regions, two extracellular loops, and intra-
cellular N and C terminus. It belongs to a large family of
claudin molecules with at least 24 members. Intracellular C
terminus vary among the various claudin members. The
extracellular domains of the claudins interact differentially
with each other. Cellular claudin-1, for example, can
associate with itself and claudin-3 but not with claudin-2 in
neighbouring cells (Furuse et al., 1999). Claudin-1 is critical
in the formation of tight junctions. Fibroblasts transfected
with its gene adhere to each other by forming tight junction
structures (Furuse et al., 1998; Kubota et al., 1999). Claudins
are not only involved in cellular adhesion but may also
regulate other processes such as paracellular transport.
Claudin-1 is expressed in keratinocytes forming the living
layers of murine epidermis and is responsible for the physical
barrier function that prevents the transcutaneous loss of water
and desiccation, at least in newborn mice (Furuse et al.,
2002).
We decided to investigate the expression of claudin-1 in
murine LC. To this end, we characterized claudin-1 in
cutaneous and lymph node LC and DC from skin-draining
lymph nodes under steady-state and inflammatory condi-
tions. We investigated claudin-1 in cutaneous LC and DC
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labeled by epicutaneous application of tetramethylrhod-
amine-isothiocyanate (TRITC) and in labeled cells that have
migrated to draining lymph nodes. Further, we employed a
bone marrow culture system that permits the induction of
CD207þ LC-like cells and LC that have migrated from skin
in organ culture.
RESULTS
Claudin-1 in epidermal LC
Epidermal sheets from steady-state epidermis and skin
sections were stained with polyclonal (p) antibody (Ab) to
intracellular C-terminal determinants of claudin-1 and mAbs
to histocompatibility complex (MHC) class II or CD207
(langerin, clone 929F3) and analyzed by confocal laser
microscopy. The claudin-1 Ab labeled interkeratinocyte
boundaries as expected. In addition, claudin-1 staining was
also present at sites of dendrites and at perinuclear location of
LC (Figure 1a, b, and e), suggesting that LC express claudin-1
epitopes. Isotype and normal rabbit serum controls were
negative. Secondary antibodies (anti-rabbit and anti-rat) did
not cross-react across species barriers (rat and rabbit). When
a peptide corresponding to the relevant intracellular
C-terminal claudin-1 epitopes was incubated with the
anti-claudin pAb before immunostaining, signals were
reduced to background (Figure 1c). These results confirmed
the specificity of the immunohistologic labeling. The staining
pattern of keratinocytes and LC with the claudin-1 pAb was
also demonstrated in three-dimensional reconstructions of
epidermis (Figure 1d).
To confirm these results, trypsinized epidermal cell
suspensions were labeled with CD207 (clone 205C1) and
major MHC class II m Ab combinations. Claudin-1 was
detected with a mAb, in addition to the pAb. Cells were
analyzed by flow cytometry. The vast majority of CD207þ
and MHC class IIþ cells were claudin-1þ (Figure 2a). These
results were reproducible with another mAb to CD207 (clone
929F3, data not shown). Claudin-1 staining in both CD207þ
and CD207 cells was abolished by pre-incubation of the
mAb (Figure 2b) and the pAb (data not shown) with the C-
terminal peptide but not with an irrelevant peptide, indicating
that it included epitopes detected by the pAb and the mAb.
A subpopulation of CD207 and MHC class II cells
(keratinocytes) labeled with the anti-claudin-1 Abs as
expected (Figure 2a and b). CD11cþ and/or
CD11bþCD207 or MHC class IIþCD207 cells prepared
freshly from the dermis were negative for claudin-1 (Figure 3).
When dispase was used for dermoepidermal separation, the
number of CD207þ cells recovered from steady-state dermis
was too low to make a reliable statement regarding claudin-1
expression. When we used trypsin for dermoepidermal
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Figure 1. Epidermal and lymph node LC express claudin-1 in situ. (a–c) Epidermal sheets, (e) skin, or (f) lymph node sections were stained with mAb to CD207
(929F3) or MHC class II (green, red in panel e) and a pAb to claudin-1 (red, green in panel e) pre-absorbed or not with the relevant peptide (þ peptide)
corresponding to intracellular epitopes of claudin-1. The sections and sheets were counterstained or not with DAPI. DAPI, DAPI counterstaining plus green
and red fluorescence overlay. (d) Three-dimensional reconstruction of epidermal sheet stained as in panel a. (e) CD207þ claudin-1þ cell (yellow arrow);
CD207claudin-1þ cell (white arrow). Bar¼ 8.2mm in panels a and c, 8.4 mm in panel b, and 6.6 mm in panel e and 9.1mm in panel f.
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separation, many CD207þ claudin-1þ cells were observed
but may represent contamination from epidermal (follicular)
LC as described (Tse and Cooper, 1990, data not shown).
Claudin-1 in LC of skin-draining lymph nodes
Sections of skin-draining lymph nodes were labeled for
CD207(929F3) and claudin-1 with the pAb. Lymph node LCs
were identified as large cells with dendrites among smaller
cells (lymphocytes) as described. CD207þ cells labeled for
claudin-1 in variable intensity (Figure 1f). We also detected
dendritically shaped claudin-1þ cells, which were clearly
CD207 (Figure 1f, white arrow), suggesting that DC other
than LC in the lymph node express claudin-1.
Claudin-1 expression in skin-draining lymph nodes was
further studied by flow cytometry. CD207þ (205C1 or
929F3) lymph node cells were specifically labeled with the
mAb to claudin-1 (Figure 4a and b). Douillard et al. (2005)
described recently CD8þCD207þ cells in lymph nodes that
may correspond to lymph node-resident LC derived from the
blood, in addition to the CD8 skin-derived LC. To see
whether both subsets of CD207þ lymph node LC express
claudin-1, CD4 and B220-depleted lymph node cells were
additionally labeled for CD8. Both CD8þ and CD8 CD207
LC in Balb/C mice were claudin-1þ (Figure 4c and d). These
results were confirmed in low-density lymph node cells from
C57BL/6 mice (data not shown).
To further characterize the CD207 cells in the lymph
node that were claudin-1þ , we stained low-density lymph
node cells with CD207(205C1), CD8, CD11b, and CD11c or
CD207, and CD205 mAb. CD11cþ but not CD11c cells
stained for claudin-1 (Figure 4e). We found most CD207þ
cells in the CD11b intermediate CD11c intermediate fraction
(data not shown) as described by Iezzi et al. (2006). All
CD11bþ and/or CD11cþCD207 cell fractions specifi-
cally stained for claudin-1 (Figure 4f). CD205þCD207 and
the CD8þCD11cþ cells were also claudin-1þ (Figure 4g).
We next wanted to confirm claudin-1 protein in LC. To
this end, CD207þ lymph node cells from transgenic mice
expressing enhanced green fluorescent protein (EGFP) under
the control of the CD207 promoter (Kissenpfennig et al.,
2005) were sorted and subjected to Western blotting. The
blots showed positive and specific signals at the 23 kDa
region with the pAb to claudin-1 in EGFPþ -sorted lymph
node cells (Figure 5a), confirming the presence of claudin-1
protein in lymph node LC.
Claudin-1 in bone marrow cultures
As reported by Valladeau et al. (2002), we found CD207
(205C1)þ cells in a subpopulation of murine bone marrow
cell cultures supplemented with GM-CSF, IL-4 and transform-
ing growth factor (TGF)-b with or without FMS-like tyrosine
kinase 3 ligand (Flt3-ligand). Western blotting with the pAb to
claudin-1 confirmed the presence of this protein in these
cultures (Figure 5b). Cultures without TGF-b produced a
much weaker signal for claudin-1 in three independent
experiments, indicating that this cytokine-induced accumula-
tion of claudin-1 protein. A subpopulation of CD207þ and
CD207 cells specifically labeled for claudin-1 by flow
cytometry (Figure 6). Similar results were obtained with
another mAb to CD207 (929F3, data not shown). RT-PCR of
cultured cells revealed positive signals for claudin-1 but not
other epithelial claudins (claudin-3, -4, -6, -8, and -12,
Turksen and Troy, 2004; Figure 5c). Addition of TGF-b leads
to a stronger claudin-1 band, indicating that this cytokine also
induced accumulation of claudin-1 at the mRNA level. There
was no effect of Flt3-ligand on claudin-1 expression.
Epidermal cells and low-density lymph node cells were
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Figure 3. Claudin-1 is not expressed in dermal DC. Freshly prepared dermal
cells from steady-state skin were stained with mAb to CD207, CD11b,
CD11c, and claudin-1 or to CD207, MHC class II, and claudin-1. Results are
representative for at least three experiments. Relevant peptide, preabsorption
with relevant peptide.
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Figure 2. Flow cytometric demonstration of claudin-1 in epidermal LC.
Fixed and permeabilized epidermal cell suspensions were stained with mAb
to CD207 (205C1) or MHC class II and claudin-1. Results are representative
for at least three experiments. Relevant peptide, preabsorption with relevant
peptide. Irrelevant peptide, preabsorption with irrelevant peptide.
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positive for claudin-1 but negative for claudin-3 mRNA
(Figure 5d).
Claudin-1 in migrating cutaneous DC
LCs migrate out of skin in organ culture. We used this culture
system to characterize claudin-1 expression. After 2 (Figure
7a) or 3 (data not shown) days of culture, CD207þ (205C1)
cells stained with claudin-1. The vast majority of
CD11cþCD207 cells, referred to as migrating dermal DC
cells (Stoitzner et al., 2003), did not label for claudin-1
(Figure 7a). A minor claudin-1þCD11cCD207 subset
was observed under these conditions (Figure 7b).
Claudin-1 under inflammatory conditions
We asked whether claudin-1 may be modulated in CD207þ
cells under inflammatory conditions. Murine ear skin was
painted with DNFB. After 6 hours, the animals were killed
and epidermis was separated from dermis by trypsin or
dispase, and epidermal and dermal cells were prepared.
Epidermal LC identified with CD207 (205C1; Figure 8) or
MHC class II (data not shown) were claudin-1þ . Claudin-1
signals in CD207þ cells under these inflammatory condi-
tions did not differ from steady state.
LCs migrate to skin-draining lymph nodes at increased
numbers under inflammatory conditions (Stoitzner et al.,
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2003) and can be tracked with epicutaneously applied
fluorochrome. To investigate claudin-1 expression in LC after
migration from skin, we used the transgenic mice expressing
EGFP under the control of the CD207 promoter. Abdominal
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Figure 5. Claudin-1 protein and mRNA in LC. Sorted EGFPþ (2 104) and
EGFP cells (2105) from CD4, CD8, and B220-depleted, total (total LN cells)
skin-draining lymph node cells and enriched cells (CD4/CD8/B220 cells,
2 105) from (a) langerin/EGFP transgenic mice (b) and bone marrow cells
cultured in GM-CSF, IL-4, with or without Flt3-ligand, (b and c) with or
without TGF-b, (d) epidermal cells, or (d) low-density lymph node cells
were subjected to (a and b) Western blotting or (c and d) RT-PCR.
(a and b) Claudin-1 signals in Western blots from the 23 kDa region,
b-actin signals the 47 kDa region. RT-PCR signals for claudin-1 after 35
cycles, RT-PCR signals for GAPDH after 25 cycles.
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Figure 6. Claudin-1 in LC-derived from bone marrow. Bone marrow-derived
LCs were stained for claudin-1, CD207, and CD11c. Results are
representative for at least three experiments. Relevant peptide, preabsorption
with relevant peptide.
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Figure 7. Claudin-1 in DC migrating from skin organ cultures. DC migrating
from skin organ cultures after 2 days were stained with mAb to CD207,
claudin-1, and CD11c. Results are representative for at least three
experiments. Relevant peptide, preabsorption with relevant peptide.
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Figure 8. Claudin-1 in epidermal LC after DNFB painting. Epidermal cells
were stained with mAb to CD207 and claudin-1 6 hours after DNFB painting.
Results are representative for at least three experiments. þDNFB, after DNFB
painting.
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skin of naı¨ve mice was painted with the fluorochrome TRITC
and skin-draining lymph nodes were analyzed after 3 days
(Kissenpfennig et al., 2005). A subpopulation of
TRITCþ EGFPþ and TRITCþ EGFP including
TRITCþCD11bþ EGFP lymph node cells was positive for
claudin-1, demonstrating that skin-derived LC continue to
express claudin-1 (Figure 9). These results were confirmed
with lymph node cells from nontransgenic mice labeled with
the CD207 mAb 205C1 (data not shown). EGFPþ or
CD207þ TRITCþ and EGFPþ or CD207þTRITC cells,
respectively, exhibited the same staining intensity for
claudin-1 (data not shown), suggesting that TRITC uptake
and transport to lymph nodes by LC was not associated with
significant modulation of this protein. These experiments
showed further the presence of TRITCþ non-LC in the lymph
node, among them CD11bþ cells of which a subpopulation
is claudin-1þ .
DISCUSSION
The in situ demonstration of claudin-1 in epidermal LC was
complicated by expression of this molecule by neighboring
keratinocytes. The fixation method used for epidermal sheets
or skin sections may induce artifacts making the precise
assignment of immunolabel to LC or keratinocytes difficult,
although the confocal images and the three-dimensional
reconstructions were very suggestive (Figure 1a–e). Flow
cytometry, however, clearly indicated the presence of
claudin-1 epitopes in LC (Figure 2a and b). Any nonspecific
binding was ruled out by absorption with a peptide
corresponding to the relevant intracellular C-terminal clau-
din-1 epitopes. The relevant peptide inhibited the binding of
both the pAb and the mAb, indicating that the peptide
contained epitopes detected by both reagents. The pAb but
not the mAb are known to cross-react with claudin-3. We
found no claudin-3 mRNA by RT-PCR in murine epidermal
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Figure 9. Claudin-1 is expressed in TRITC-traced LC and CD11bþCD207 cells after migration to the lymph node. Low-density lymph node cells from
langerin-EGFP transgenic mice were stained with mAb to claudin-1 and CD11b 3 days after TRITC painting. Results are representative of three experiments.
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cells or low-density lymph node cells (Figure 5d). Together,
this strongly suggests that the observed immunolabeling was
detecting claudin-1 epitopes.
The expression of claudin-1 by a subpopulation of
keratinocytes also rendered difficult the molecular demon-
stration of claudin-1 in LC. As it was impossible in our hands
to physically separate LC and keratinocytes to sufficient
purity, we used two different approaches. One was to employ
transgenic mice in which EGFP is expressed under the control
of the promoter of CD207 (Kissenpfennig et al., 2005) and
cell sorting of lymph node cells devoid of epithelial cells. The
other approach consisted in the use of bone marrow cultures
that generate CD207þ LC-like cells. Both approaches were
successful for the demonstration of claudin-1 protein (Figure
5a and b). We used EGFPþ and EGFP sorted CD4, CD8,
and B220-depleted lymph node cells to perform Western
blotting. Claudin-1 protein was identified in the EGFPþ but
not in the EGFP cell fraction. Presumably, the frequency of
non-LC lymph node DC in the EGFP cell fraction was too
low to detect claudin-1 signals. In bone marrow-derived LC
cultures, we identified CD207þ claudin-1þ as well as
CD207claudin-1þ cells (Figure 6). Under the conditions
used here, bone marrow cultures may generate multiple DC
subsets and precursors that may not have acquired CD207.
Nonetheless, this culture system permitted us to demonstrate
claudin-1 mRNA and protein accumulation in response to
TGF-b (Figure 5b and c), the cytokine that is critical for the
induction of epidermal LC (Borkowski et al., 1996, 1997;
Strobl et al., 1996). The addition of Flt3-ligand did not
modulate claudin-1 levels (Figure 5b; data not shown). The
RT-PCR experiments were positive for claudin-1 but no other
epidermal claudin, indicating restricted expression of claudin
family genes in LC. Cell sorting with the CD207 mAb 205C1
coupled to Alexa488 was not possible in our hands without
permeabilization of cells when we used epidermal, lymph
node, or bone marrow culture cells, although the manufac-
turer claims that this Ab detects an extracellular CD207
epitope. Our results with another CD207 mAb, (clone 929F3)
however, closely correlated with data obtained with 205C1
in epidermal cell suspensions, bone marrow cultures and
lymph nodes when analyzed in permeabilized cells (data not
shown). In agreement with a previous report (Douillard et al.,
2005), the presence of a small subpopulation of
929F3þ 205C1 cells aside from a larger 929F3þ 205C1þ
population in lymph node cells was confirmed in our hands
(data not shown).
Claudin-1 expression in epidermal LC was not grossly
modulated 6 hours after DNFB painting (Figure 8). Further,
TRITCþ and TRITCEGFPþ (or TRITCþCD207þ and
TRITCCD207þ ) cells in the lymph node had the same
claudin-1 staining intensity (data not shown). Together with
the clear claudin-1 signal in LC that migrated from skin to the
culture dish (Figure 7a), this suggests that claudin-1 is not
grossly modulated by migration and/or inflammatory stimuli.
CD207þCD8 cells in skin-draining lymph nodes are
thought to represent epidermal LC that have migrated. We
demonstrated claudin-1 in these cells under steady-state and
inflammatory conditions. We used the fluorochrome TRITC
to track LC in lymph nodes using either transgenic mice
expressing EGFP under the control of the langerin promoter
(Figure 9) or CD207 mAb to identify LC (data not shown),
permitting the formal demonstration that migrating LC
express claudin-1 under inflammatory conditions (TRITC skin
painting) in the draining lymph node with both approaches.
Although claudin-1 was not found in other cutaneous
antigen-presenting cells than LC, we found other DC subsets
in the lymph node expressing claudin-1. CD207þCD8þ
cells in the lymph node are thought to represent blood-borne
nonmigrating, lymph node resident LC (Douillard et al.,
2005). These cells clearly expressed claudin-1 epitopes
(Figure 4d). Claudin-1 expression in LC may thus not be
associated with skin origin. The CD207CD8þ cell fraction
staining for claudin-1 (Figure 4d) may contain
CD8þCD11cþ blood-borne, resident lymph node DC with
high capacity to cross-present antigen (Shortman and Liu,
2002). Claudin-1 expression was demonstrated in this latter
subset (Figure 4g). All cell fractions defined by CD11b and
CD11c or CD205 among CD207 DC were claudin-1þ
(Figure 4e and f). This indicated that most DCs in skin-draining
lymph nodes express claudin-1 under steady-state conditions.
The fact that CD11bþCD207 cells were claudin-1þ
(Figure 4f) suggested that DC migrating from dermis under
noninflammatory conditions increase their claudin-1 protein
because dermal DC did not express detectable claudin-1.
CD11b is considered as a marker of skin migration in draining
lymph node DC (He et al., 2006). This was supported by the
observation that all CD205þCD207 lymph node cells were
claudin-1þ (Figure 4g). Aside from lymph node-resident
CD8þCD11cþ lymph node DC, skin migrating DC,
including LC and dermal DC, express CD205 (He et al.,
2006). Furthermore, the TRITC tracking experiment directly
demonstrated that TRITCþCD11bþCD207 DC in the
lymph node expressed claudin-1 (Figure 9). It is, thus, possible
that CD207 DC migrating from skin upregulated claudin-1
expression also under inflammatory conditions, once their
migration to the lymph node has been initiated or completed.
Candidates are dermal DC that are resident in steady-state
skin (Stoitzner et al., 2003) or blood-borne monocytes that
infiltrate inflammatory foci in skin, which can differentiate
into DC-like cells and migrate to the draining lymph node
(Randolph et al., 1999; Le Borgne et al., 2006). Our attempts
to characterize claudin-1 in dermal antigen-presenting cells
6 hours after DNFB yielded nonreproducible results (data not
shown). Thus, it can not be ruled out that claudin-1 was
induced under inflammatory conditions in the dermis before
migration to lymph nodes.
Claudin-1 was identified recently in a DC subset in the
lung expressing CD207 (Sung et al., 2006). This subset was
CD103þ and may correspond to migrating DC. Epidermal
LC in situ do not express CD103 (Pribila et al., 2004). In our
hands, bone marrow-derived CD207þ cells were also
negative for CD103 (data not shown) and only a minor
subset of CD207þ cells in skin-draining lymph nodes was
CD103þ (data not shown). Thus, the relationship between
CD207þCD103þ claudin-1þ DC in the lung and the
claudin-1þ LC described here is currently not clear.
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In other reports, expression of claudin-1 in DC was
associated with other tight junction proteins (Rescigno et al.,
2001; Pribila et al., 2004). The technical difficulties in
localizing precisely tight junction proteins in LC in the
epidermis, the lack of specific peptides for inhibition of Ab
binding to some of the tight junction proteins, and the cell
separation issue precluded a systematic search for these
molecules. Rescigno et al. (2001) have shown constitutive
and inducible expression of several tight junction proteins
(ZO-1, occluding, and claudin-1) in a DC line that can send
dendrites across an epithelial monolayer, and thus internalize
and transport bacteria transepithelially. Pribilia et al. (2004)
demonstrated ZO-2, an intracellular protein associated with
transmembrane proteins of the tight junction, in addition to
claudin-1 and -7 in a subset of CD103þCD207þ DC in the
lung. We have preliminary data supporting the expression of
ZO-2 in epidermal LC (data not shown).
We screened 12 murine epidermal LC in situ by
transmission electron microscopy and were unable to identify
tight junction-like structures. The characterization of the
adhesive functionality of the extracellular domains of
claudin-1 is complicated by the fact that it can interact with
numerous other members of the claudin family based on its
amino-acid sequence similarity. Trypsin may have digested
the extracellular domain in freshly prepared epidermal cells.
The conserved structure of the extracellular loops of claudins
is also probably the reason for the lack of Ab to these
domains. Mice with genetic deletion of the claudin-1 gene
may be helpful in elucidating its functionality and function in
LC and lymph node DC (Furuse et al., 2002), although they
die in the neonatal period owing to epidermal barrier
dysfunction.
In conclusion, we report here the expression of the tight
junction protein claudin-1 in LC in the epidermis and after
migration to skin-draining lymph nodes under steady-state
and inflammatory conditions. All non-LC DC subsets in skin-
draining lymph nodes, including non-LC DC that have
migrated from skin, expressed claudin-1. Thus, claudin-1 in
DC is independent of intraepithelial location and may be
involved in migration to lymph nodes, or have functions
within the lymph node.
MATERIALS AND METHODS
Mice
C57BL/6, BalbC, or C3H mice were purchased from the animal
facility at the Centre Me´dicale Universitaire (Geneva, Switzerland)
or Charles River (l’Arbresle, France) and used at 4–16 weeks of
age. For some experiments, Langerin-EGFP knock-in mice were
used (kind gift from Dr Adrien Kissenpfennig, Belfast, UK). The
experiments were approved by the State Veterinarian’s Office
(Geneva, Switzerland) and performed according to the Federal
Law (Switzerland).
Cell preparations
Bone marrow-derived DC/LC. Bone marrow cells were cultured
for 7–8 days in Iscove’s medium (Sigma, St Louis, MO) supplemented
with 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine
solution, 0.05 mM b-mercaptoethanol, and 10% fetal bovine serum
(all from Sigma) in presence of 25 ng/ml IL-4 (R&D, Minneapolis,
MN or ImmunoTools, Friesoythe, Germany) and 25 ng/ml GM-CSF
(R&D or ImmunoTools). Cells were either grown in presence or
absence of 8 ng/ml TGF-b (Strathmann Biotec, Hamburg, Germany)
and 10 ng/ml Flt3-ligand (R&D or ImmunoTools).
Lymph node DC/LC. Superficial inguinal, axillary, and brachial
LN were digested for 30 minutes at 371C in RPMI 1640 (Gibco/
Invitrogen, Paisley, Scotland) containing 10% fetal bovine serum,
1 mg/ml collagenase D (Roche, Penzbeg, Germany) and 40 mm/ml
DNase I (Sigma). LN cells were depleted with GK1.5 (CD4), 5367
(CD8), 14.8 (CD220), and sheep anti-rat magnetic beads (Dynal,
Osio, Norway) or spun over a 60% Percoll gradient to obtain low-
density cells.
Epidermal LC. The dorsal and ventral ear skin was incubated in
Hanks-balanced salt solution (Sigma) containing 0.5% of trypsin
(Sigma) or DMEM (Sigma) containing 1.2 U/ml dispase (Roche). The
epidermis was separated from the dermis and incubated further in
Hanks-balanced salt solution containing 0.5% trypsin in the case of
dispase separation.
Dermal DC. Dermis freed from epidermis by trypsin or dispase was
further incubated at 371C for 1 hour in RPMI1640 containing 10%
fetal bovine serum, 5 mg/ml collagenase D (Roche), 0.37 mg/ml
Dnase I (Sigma), and 2.2 mg/ml hyaluronidase (Sigma).
DC migration from mouse ear skin on culture. The dorsal and
ventral ear skin was incubated in 24-well plates (Nalge Nunc,
Rochester, NY) in DMEM supplemented with 100 U/ml penicillin,
0.1 mg/ml streptomycin, 2 mM L-glutamine, and 0.05 mM b-mercap-
toethanol and 10% fetal bovine serum for 2–3 days. The ear leaflets
were removed and floating cells recovered.
Skin painting
Mice were painted with 20 ml of 0.5% 2,4-DNFB (Sigma) in acetone/
olive oil (4:1) on the dorsal and ventral side of both ears and killed
after 6 hours. TRITC (Molecular Probes, Eugene, OR) was diluted to
10% in dimethylsulfoxide. This stock was diluted further to 0.5% in a
1:1 acetone/dibutylphtalate mix. Hundred microliters were painted
onto the abdomen.
Immunostaining
Flow cytometry. Cells were fixed in Cytofix/Cytoperm (BD
Pharmingen, Franklin, NJ) for 20 minutes on ice followed by two
wash steps using Perm/Wash buffer (BD Pharmingen). All stainings
were performed in Perm/Wash buffer. The following antibodies were
used: Anti-langerin (CD207, rat IgG1, clone 929F3, kind gift from Dr
Stephan Beissert, Department of Dermatology, Munster, Germany,
or clone 205C1 mouse IgM coupled to Alexa488 (Dendritics-AbCys,
Paris, France) followed by goat anti-rat FITC (Caltag/Invitrogen,
Carlsbad, CA), goat-anti-rat A488 (Molecular Probes Cat no.
A11006) or goat anti-rat-biotin (BD Pharmingen), and Streptavidin-
APC (BD Pharmingen) or clone 929F3 directly coupled to A488 or
546 or clone 205C1 coupled to biotin (all from Dendritics-AbCys)
followed by Streptavidin-PE (Caltag), anti-claudin-1 mAb (mouse
IgG1, Zymed, San Francisco, CA) labeled with APC using a Zenon
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mouse IgG1 labeling kit (Molecular Probes) and anti-MHC class II-PE
(ratIgG2b, BD Pharmingen), CD8a-PE (rat IgG2a, BD Pharmingen),
CD11b-PE-Cy7 (rat IgG2b, BD Pharmingen), CD11c (hamster IgG1,
BD Pharmingen) coupled to PE or APC or CD205 coupled to A488
(rat IgG2a, Serotec, Kidlington UK). Multiparameter analyses were
acquired on a FACScalibur (BD Pharmingen) and analyzed with
Cellquest software (BD Pharmingen).
Epidermal sheets. The dorsal and ventral ear skin was incubated
for 20 minutes at 371C in 0.5 M NH4SCN. The epidermis was fixed in
a 1:1 mix of acetone/methanol. Epidermal sheets were incubated
anti-claudin-1 (polyclonal rabbit, Zymed) followed by goat anti-
rabbit Alexa488 (Molecular Probes Cat no. A11008) in combination
with anti-langerin or anti-MHC II mAb and subsequently with
secondary antibodies (goat anti-rat FITC, Alexa488 or Alexa568, and
goat anti-rabbit Alexa568 or Alexa488). Sheets were mounted with
Vectashield containing DAPI and images were acquired on a
confocal laser microscope (LSM 510 or LSM 510 Meta, Zeiss,
Oberkochen, Germany). Three-dimensional reconstructions were
made with Imaris (Bitplane, Zurich, Switzerland) software. To
control the specificity of the claudin-1 staining, a C-terminal peptide
(Santa Cruz Technology, Santa Cruz, CA) was used for both in situ
staining and flow cytometry.
Western blots
Cells were lysed with a buffer containing NaCl 0.15 M, Tris 0.05 M,
pH 6.8, EDTA 1 mM, protease inhibitors (Roche), and Triton 1%.
Protein concentration in the supernatant was determined with a
Bradford assay (Bio-Rad, Munich, Germany). Samples were sepa-
rated by 10% SDS-PAGE gel and transferred to a nitrocellulose
membrane (Amersham, Piscataway, NJ). The blocked membrane
was incubated with anti-claudin-1 or anti-b-actin (Abcam, Cam-
bridge, UK) and subsequently with goat anti-rabbit horseradish
peroxidase (Bio-Rad, Hercules, CA). For the chemiluminescence,
ECL detection reagents (Amersham Pharmacia, Piscataway, NJ) were
used. The membrane was exposed to a film and developed using a
Kodak XP 2000 film developer device.
RT-PCR
RNA was extracted using Trizol (Gibco BRL, Invitrogen, Paisley, UK)
and chloroform (Gibco BRL) or an RNeasy Plus Mini kit (Qiagen,
Hilden, Germany). The RNA was treated with RNase-free DNase
(Promega, Madison, WI) to remove remaining DNA. RT-PCR was
performed using random primers (Promega), 10 mM dNTPs (Invitro-
gen), RNasin Plus (Promega), 5 first strand buffer, dithiothreitol,
and Superscript (Invitrogen). cDNA was then amplified by PCR using
Taq Polymerase (Invitrogen) under the following conditions:
denaturation 30 seconds, annealing at 601C for 30 seconds, and
extension at 721C for 1 minute for 35 cycles. The following primers
were used: mouse claudin-1, 50-CTGGGTTTCATCCTGGCTTC-30
and 50-TTGATGGGGGTCAAGGGGTC-30; mouse claudin-3, 50-
AAAGAATTCTGCTCCTGCCCACCGCGCGAC-30 and 50-AAACTC
GAGAAGTAGCTGCAGTGGCCACC-30; mouse claudin-4, 50-
TAGGGGGCAAGTGCACCAAC-30 and 50-CCCCAGCAAGCAGT
TAGTGG-30; mouse claudin-6, 50-ATCTTGGGGATCGTCCTGAC-
30 and 50-TTTGAGCATCAGCCACCAAG-30; mouse claudin-8, 50-
GCCTCAGTGGAGAGTGTCTG-30 and 50-AGAACAGTGCTCCTC
CAGCG-30; mouse claudin-12, 50-TAACTGGAGGAAACTGCGGC-
30 and 50-CCCCTGAGCTAGCAATAGTG-30.
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